An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Aclidinium Bromide 200 μg; Drug: Aclidinium Bromide 400 μg; Drug: Aclidinium Bromide 800 μg Sponsor: AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Condition: Pulmonary Disease, Chronic Obstructive Intervention: Drug: Aclidinium Bromide/Formoterol Fumarate 400/12μg BID Sponsor: AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials
An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects
Condition: Pulmonary Disease, Chronic Obstructive Interventions: Drug: Aclidinium Bromide 200 μg; Drug: Aclidinium Bromide 400 μg; Drug: Aclidinium Bromide 800 μg Sponsor: AstraZeneca Not yet recruiting - verified August 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 7, 2017 Category: Research Source Type: clinical trials